Quinolone M1 receptor positive allosteric modulators

Details for Australian Patent Application No. 2006322045 (hide)

Owner Merck & Co., Inc. Merck Sharp & Dohme Limited

Inventors Shipe, William D.; Hallett, David; Lindsley, Craig

Agent Spruson & Ferguson

Pub. Number AU-A-2006322045

PCT Pub. Number WO2007/067489

Priority 60/789,272 04.04.06 US; 60/742,234 05.12.05 US

Filing date 4 December 2006

Wipo publication date 14 June 2007

International Classifications

C07D 215/22 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

A61K 31/407 (2006.01) - condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine

A61P 25/16 (2006.01) Drugs for disorders of the nervous system

Event Publications

12 June 2008 PCT application entered the National Phase

  PCT publication WO2007/067489 Priority application(s): WO2007/067489

16 December 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006322046-Polymorphs of androgen receptor modulator - (N-3H-imidazo [4 , 5-B] pyridin2-yl-methyl) - 2-fluoro-4-methyl-3-oxo-4-aza-androstl-en-17 . beta . -carboxamide

2006322038-Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate